Epigral delivered a record Q4 FY26: revenue ₹736 crore (+22% QoQ), EBITDA ₹169 crore (23% margin), PAT ₹82 crore. FY26 revenue ₹2,542 crore (EBITDA margin 22%). Post-conflict ECU spike to ₹37,000 (from Q4's ₹30,000) is a FY27 tailwind. FY27 guidance: 10-12% volume growth with new capacity commissioning. Good sentiment, medium confidence (record Q4, ECU tailwind is partially transient, new capacity ramp provides structural volume growth).
Headline Numbers
| Metric | FY26 / Q4 FY26 | Notes |
|---|---|---|
| Q4 Revenue | ₹736 crore | +22% QoQ; record |
| FY26 Revenue | ₹2,542 crore | -1% YoY |
| Q4 EBITDA | ₹169 crore | 23% margin |
| FY26 EBITDA Margin | 22% | — |
| Q4 PAT | ₹82 crore | 11% margin |
| Net Debt | ₹508 crore | — |
| FY26 Capex | ₹394 crore | New capacity |
| Q4 ECU Realisation | ₹30,000 | — |
| Current ECU (post-conflict) | ₹37,000 | +23% vs Q4 |
| FY27 Volume Growth | 10-12% | Guidance |
What Drove the Results
- Q4 revenue +22% QoQ — volume recovery + ECU improvement: Epigral's record Q4 came from volume recovery after a challenging FY26 (full-year revenue -1% YoY). Chlor-alkali demand improved in Q4 as end-markets (agrochemicals, textiles) recovered, and Epigral's new downstream capacity contributed incremental volume. The Q4 ECU at ₹30,000 was still recovering from mid-FY26 lows — Q4 operating leverage on recovering volumes drove EBITDA to 23%.
- Post-conflict ECU ₹37,000 — 23% upside to Q4 realisations: ECU spiked from ₹30,000 to ₹37,000 after the Iran conflict disrupted Middle East chlor-alkali supply. India exports caustic soda to Southeast Asia and receives a global price signal. At ₹37,000 ECU in Q1 FY27 (vs ₹30,000 in Q4 FY26), Epigral's per-unit margin improves substantially. The ECU spike adds ₹50-80 crore to FY27 EBITDA vs Q4-run-rate, assuming volumes hold.
- FY27 volume growth 10-12% — new capacity commissioning: Epigral's ₹394 crore FY26 capex is adding downstream specialty chemical capacity that commissions in FY27. Volume growth at 10-12% is the structural growth lever — at constant ECU, this adds ₹20-25 crore EBITDA annually. The combination of ECU upside + volume growth creates a positive FY27 scenario.
- EBITDA margin recovery 22-23% — operational leverage at higher volumes: FY26's 22% EBITDA margin (on -1% revenue) demonstrates cost discipline. At higher FY27 volumes and ECU ₹37,000, EBITDA margin could expand to 24-26%, generating ₹250-300 crore EBITDA — a significant step-up from FY26's ~₹223 crore (estimated at 22% of ₹2,542 crore).
- Net debt ₹508 crore — watch for deleveraging in FY27: Post-capex FY26 net debt at ₹508 crore is elevated at ~2.3x EBITDA. As FY27 cash flows improve (higher ECU + volume growth), deleveraging becomes the priority. Management is expected to use FY27 cash flows to reduce debt. Each ₹100 crore debt reduction at 9-10% interest rate adds ₹9-10 crore to PAT.
What Management Said
Management was constructive on FY27 with a watchful eye on ECU sustainability. On Q4: "Record Q4 — volume recovery and improving ECU are working together. Our new capacity is contributing." On ECU: "Current ECU is ₹37,000 — significantly better than Q4's ₹30,000. Iran conflict has tightened global caustic soda supply. We are monitoring sustainability." On FY27: "10-12% volume growth target — our new capacity is commissioning. We are confident on volume." On margins: "23% Q4 margin — as volumes grow and ECU remains elevated, we expect margin improvement." On debt: "Net debt ₹508 crore — we will deleverage from FY27 cash flows."
Key Tailwinds and Risks
Tailwinds:
- ECU spike to ₹37,000 (post-conflict) — significant Q1 FY27 margin tailwind
- New capacity commissioning — 10-12% volume growth structurally adds EBITDA
- Downstream specialty mix improvement — higher-value derivatives at better margins than commodity chlorine
- Agrochemical/pharma demand recovery — key end-markets improving
- Chlor-alkali supply discipline — India's regulated sector limits new capacity proliferation
Risks:
- ECU normalisation — ₹37,000 partially transient; ₹28,000-32,000 is historical norm
- Power cost inflation — electricity is 40%+ of chlor-alkali manufacturing cost; tariff hikes compress margins
- Net debt ₹508 crore — leverage at ~2.3x EBITDA; tight interest cover in downturns
- Capacity ramp time — new commissioning takes 6-9 months to reach full utilisation
- Cyclical pricing — chlor-alkali can swing 30%+ in a year; visibility limited beyond 2-3 quarters
StockMirror AI Signal Summary
| Signal | Reading |
|---|---|
| Overall Sentiment | Good |
| Management Confidence | Medium |
| Prepared Remarks | Good — record Q4, ECU tailwind, volume growth guidance |
| Q&A Sentiment | Neutral-Good — candid on ECU transience, confident on volume |
| Revenue Growth | Recovery — Q4 record +22% QoQ; FY27 10-12% volume growth |
| Margin Direction | Improving — 23% Q4; ECU ₹37,000 is a FY27 upside catalyst |
| Earnings Quality | Moderate — ECU-linked profitability; new capacity adds structural dimension |
Track Epigral's full AI earnings breakdown — ECU trajectory, volume growth, and margin recovery — at Epigral's earnings page.
Key Takeaways
- Q4 FY26 record revenue ₹736 crore (+22% QoQ), EBITDA 23%, PAT ₹82 crore
- FY26 revenue ₹2,542 crore; EBITDA margin 22%; net debt ₹508 crore
- Post-conflict ECU ₹37,000 vs Q4 ₹30,000 — meaningful Q1 FY27 tailwind
- FY27: 10-12% volume growth from new capacity; ECU upside provides additional margin lever
- Deleveraging in FY27 from improved cash flows is key PAT growth driver
Related: Navin Fluorine Q4 FY26 · Granules India Q4 FY26
Disclaimer: This article is for informational purposes only and does not constitute investment advice. StockMirror's AI analysis is based on publicly available earnings transcripts and BSE/NSE filings. Please consult a SEBI-registered financial advisor before making investment decisions.